

Clinical Oversight Review Board (CORB) Criteria for Prescribing Belinostat (Beleodaq)

Non-Formulary **belinostat (Beleodaq)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **belinostat (Beleodaq)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an oncologist or hematologist
- Diagnosis of primary T-cell lymphoma (PTCL) **OR** cutaneous T-cell lymphoma (CTCL)
- Prior combination chemotherapy
- Progression after romidepsin (Istodax)